Overview

Zanubrutinib in Participants With Active Proliferative Lupus Nephritis

Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of zanubrutinib added to standard of care as measured by complete renal response for participants with active proliferative lupus nephritis
Phase:
Phase 2
Details
Lead Sponsor:
BeiGene
Treatments:
Zanubrutinib